Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system

Background Among diffusely infiltrative gliomas in adults, 20%-30% contain a point mutation in isocitrate dehydrogenase 1 (IDH1mut), which increases production of D-2-hydroxyglutarate (D2HG). This is so efficient that D2HG often reaches 30 mM within IDH1mut gliomas. Yet, while up to 100 µM D2HG can be detected in the circulating cerebrospinal fluid of IDH1mut glioma patients, the exposure of nonneoplastic cells within and surrounding an IDH1mut glioma to D2HG is unknown and difficult to measure directly. Methods Conditioned medium from patient-derived wild type IDH1 (IDH1wt) and IDH1mut glioma cells was analyzed for D2HG by liquid chromatography-mass spectrometry (LC-MS). Mathematical models of D2HG release and diffusion around an IDH1mut glioma were independently generated based on fluid dynamics within the brain and on previously reported intratumoral and cerebrospinal D2HG concentrations. Results LC-MS analysis indicates that patient-derived IDH1mut glioma cells release 3.7-97.0 pg D2HG per cell per week. Extrapolating this to an average-sized tumor (30 mL glioma volume and 1 × 108 cells/mL tumor), the rate of D2HG release by an IDH1mut glioma (SA) is estimated at 3.2-83.0 × 10-12 mol/mL/sec. Mathematical models estimate an SA of 2.9-12.9 × 10-12 mol/mL/sec, within the range of the in vitro LC-MS data. In even the most conservative of these models, the extracellular concentration of D2HG exceeds 3 mM within a 2 cm radius from the center of an IDH1mut glioma. Conclusions The microenvironment of an IDH1mut glioma is likely being exposed to high concentrations of D2HG, in the low millimolar range. This has implications for understanding how D2HG affects nonneoplastic cells in an IDH1mut glioma.

[1]  Steven J. M. Jones,et al.  Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1 , 2017, Proceedings of the National Academy of Sciences.

[2]  J. Golfinos,et al.  Mutant IDH1 and seizures in patients with glioma , 2017, Neurology.

[3]  A. M. Houghton,et al.  Mutant IDH1 regulates the tumor-associated immune system in gliomas , 2017, Genes & development.

[4]  J. Costello,et al.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas , 2017, The Journal of clinical investigation.

[5]  M. Gilbert,et al.  Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. , 2017, Cancer research.

[6]  Gregory A. Breuer,et al.  2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.

[7]  E. Maher,et al.  Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Kondziolka,et al.  Mutant IDH1 and thrombosis in gliomas , 2016, Acta Neuropathologica.

[9]  Erwin G. Van Meir,et al.  Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase , 2016, Clinical Cancer Research.

[10]  Andrei I Holodny,et al.  Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.

[11]  B. Rosen,et al.  Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate , 2015, Clinical Cancer Research.

[12]  V. Rangnekar,et al.  The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells , 2014, Acta Neuropathologica.

[13]  K. Ross,et al.  Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.

[14]  K. Yen,et al.  Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. , 2014, The oncologist.

[15]  Claude Preudhomme,et al.  Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Janna H. Neltner,et al.  Autophagy and oxidative stress in gliomas with IDH1 mutations , 2014, Acta Neuropathologica.

[17]  Jeffrey W. Clark,et al.  Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma , 2014, Clinical Cancer Research.

[18]  Daniel B Vigneron,et al.  Non-invasive in vivo assessment of IDH1 mutational status in glioma , 2013, Nature Communications.

[19]  M. Ross,et al.  Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2 , 2013, Nature Communications.

[20]  Benjamin L. Ebert,et al.  (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.

[21]  C. Horbinski What do we know about IDH1/2 mutations so far, and how do we use it? , 2013, Acta Neuropathologica.

[22]  O. Abdel-Wahab,et al.  The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization* , 2012, The Journal of Biological Chemistry.

[23]  A. Iafrate,et al.  Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. , 2012, Blood.

[24]  D. Margolis,et al.  Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. , 2012, Blood.

[25]  A. Krämer,et al.  Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate , 2012, Acta Neuropathologica.

[26]  S. Inoue,et al.  D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. , 2012, Genes & development.

[27]  R. Verhaak,et al.  Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.

[28]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[29]  S. Weiss,et al.  An in vivo patient-derived model of endogenous IDH1-mutant glioma. , 2012, Neuro-oncology.

[30]  Mitchel S. Berger,et al.  Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas , 2012, Science Translational Medicine.

[31]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[32]  K. Kinzler,et al.  Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome , 2011, Proceedings of the National Academy of Sciences.

[33]  A. von Deimling,et al.  Increased levels of 2‐hydroxyglutarate in AML patients with IDH1‐R132H and IDH2‐R140Q mutations , 2010, European journal of haematology.

[34]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[35]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[36]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[37]  U. Del Monte Does the cell number 109 still really fit one gram of tumor tissue? , 2009, Cell cycle.

[38]  M. Wajner,et al.  Mitochondrial energy metabolism is markedly impaired by D-2-hydroxyglutaric acid in rat tissues. , 2005, Molecular genetics and metabolism.

[39]  M. Wajner,et al.  D‐2‐hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats , 2003, The European journal of neuroscience.

[40]  Jeffrey W. Clark,et al.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. , 2012, The oncologist.

[41]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[42]  J. Uhm An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .